We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Read MoreHide Full Article
Key Takeaways
IDEXX raised 2026 EPS guidance to $14.69-$14.94 after Q2 earnings rose 18% to $4.27 per share.
Recurring diagnostics sales up 10% organically as utilization, volumes and newer-product adoption increased.
Margins expanded 140 bps, while softer U.S. veterinary visits and FX remain key operating headwinds.
IDEXX Laboratories, Inc. (IDXX - Free Report) paired a second-quarter earnings beat with faster recurring diagnostics growth, wider margins and a higher 2026 earnings outlook. The results show operating momentum holding up even as U.S. veterinary traffic remains soft.
The updated guidance also separates underlying demand from currency pressure. Higher diagnostic utilization, product adoption and international expansion are supporting growth, while weaker wellness visits remain the main operating risk.
Second-quarter earnings reached $4.27 per share, up 18% year over year and 8.1% above the Zacks Consensus Estimate. Revenues rose 10% to $1.22 billion and exceeded the consensus mark by 1.3%.
Companion Animal Group Diagnostics recurring revenues increased 10% organically. Higher volumes, greater testing utilization and adoption of newer offerings helped sustain growth despite softer U.S. veterinary visits.
IDXX Raises EPS View After Stronger Quarterly Profit
IDEXX raised its 2026 earnings outlook to $14.69-$14.94 per share from $14.45-$14.90. The revision followed a quarter in which operating profit increased 14% to $425.6 million.
Per the Zacks Consensus Estimate, IDXX’s earnings for 2026 is pegged at $14.81.
Image Source: Zacks Investment Research
Operating margin expanded 140 basis points to 35%, while gross margin also improved 140 basis points to 64%. Recurring revenue volume gains, operational productivity and net price realization helped convert revenue growth into stronger profitability.
IDXX Guidance Balances Growth With Currency Pressure
The company updated 2026 revenue guidance to $4.70-$4.75 billion from $4.68-$4.76 billion. It now expects reported revenue growth of 9.1-10.3% and organic growth of 8.5-9.7%.
The midpoint rose $5 million despite a projected $15-million headwind from updated foreign-exchange assumptions. Currency can therefore weigh on reported growth without changing the underlying demand picture, and management expects about a 70-basis-point currency drag on third-quarter reported revenue growth.
IDXX Innovation Supports the Updated Outlook
VetLab consumables revenues increased 13.6% organically, supported by higher utilization, recent launches, net new customers and an 11% increase in the global premium instrument installed base. The inVue Dx installed base topped 9,000 instruments after 1,602 second-quarter placements, while Cancer Dx surpassed 10,000 ordering clinics globally.
International Companion Animal Group Diagnostics recurring revenues advanced nearly 12% organically. IDEXX plans to expand its commercial footprint in four international countries during the remainder of 2026, adding another avenue for customer and product adoption.
Abbott Laboratories (ABT - Free Report) provides a relevant diagnostics comparison through its core laboratory, molecular and point-of-care platforms. Labcorp Holdings Inc. (LH - Free Report) offers another benchmark through its broad laboratory-services and diagnostics capabilities.
IDXX Still Contends With Softer Veterinary Traffic
U.S. same-store clinical visits declined an estimated 1.3% in the second quarter, while wellness visits fell 3.4%. Management assumes an approximately 1.5% decline in U.S. clinical visits during the second half of 2026.
Higher diagnostic intensity, broader testing menus and growth among pets aged five years and older are helping offset weaker traffic. Still, prolonged wellness softness could pressure reference laboratory demand because that testing carries greater exposure to wellness activity.
Based on short-term price targets offered by 13 analysts, the average price target for IDEXX comes to $728.31. The average price target represents an increase of 29.55% from the last closing price.
Image Source: Zacks Investment Research
IDXX Ratings Keep the Earnings Momentum in Check
The raised outlook and margin expansion support the case for durable operating momentum, but softer veterinary traffic, currency volatility and valuation keep the setup balanced. IDXX trades at 34.7X forward 12-month earnings, above the Zacks sub-industry's 26.1X multiple.
The stock currently carries a Zacks Rank #3 (Hold). Its Growth Score of A and Momentum Score of B are favorable, while the Value Score of D points to valuation as a constraint. The VGM Score of B reflects a generally positive blend of growth, momentum and value characteristics, but the #3 Rank supports a measured rather than aggressive stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Key Takeaways
IDEXX Laboratories, Inc. (IDXX - Free Report) paired a second-quarter earnings beat with faster recurring diagnostics growth, wider margins and a higher 2026 earnings outlook. The results show operating momentum holding up even as U.S. veterinary traffic remains soft.
The updated guidance also separates underlying demand from currency pressure. Higher diagnostic utilization, product adoption and international expansion are supporting growth, while weaker wellness visits remain the main operating risk.
IDXX Q2 Beat Reflects Recurring Diagnostics Strength
Second-quarter earnings reached $4.27 per share, up 18% year over year and 8.1% above the Zacks Consensus Estimate. Revenues rose 10% to $1.22 billion and exceeded the consensus mark by 1.3%.
Companion Animal Group Diagnostics recurring revenues increased 10% organically. Higher volumes, greater testing utilization and adoption of newer offerings helped sustain growth despite softer U.S. veterinary visits.
IDXX Raises EPS View After Stronger Quarterly Profit
IDEXX raised its 2026 earnings outlook to $14.69-$14.94 per share from $14.45-$14.90. The revision followed a quarter in which operating profit increased 14% to $425.6 million.
Per the Zacks Consensus Estimate, IDXX’s earnings for 2026 is pegged at $14.81.
Image Source: Zacks Investment Research
Operating margin expanded 140 basis points to 35%, while gross margin also improved 140 basis points to 64%. Recurring revenue volume gains, operational productivity and net price realization helped convert revenue growth into stronger profitability.
IDXX Guidance Balances Growth With Currency Pressure
The company updated 2026 revenue guidance to $4.70-$4.75 billion from $4.68-$4.76 billion. It now expects reported revenue growth of 9.1-10.3% and organic growth of 8.5-9.7%.
The midpoint rose $5 million despite a projected $15-million headwind from updated foreign-exchange assumptions. Currency can therefore weigh on reported growth without changing the underlying demand picture, and management expects about a 70-basis-point currency drag on third-quarter reported revenue growth.
IDXX Innovation Supports the Updated Outlook
VetLab consumables revenues increased 13.6% organically, supported by higher utilization, recent launches, net new customers and an 11% increase in the global premium instrument installed base. The inVue Dx installed base topped 9,000 instruments after 1,602 second-quarter placements, while Cancer Dx surpassed 10,000 ordering clinics globally.
International Companion Animal Group Diagnostics recurring revenues advanced nearly 12% organically. IDEXX plans to expand its commercial footprint in four international countries during the remainder of 2026, adding another avenue for customer and product adoption.
Abbott Laboratories (ABT - Free Report) provides a relevant diagnostics comparison through its core laboratory, molecular and point-of-care platforms. Labcorp Holdings Inc. (LH - Free Report) offers another benchmark through its broad laboratory-services and diagnostics capabilities.
IDXX Still Contends With Softer Veterinary Traffic
U.S. same-store clinical visits declined an estimated 1.3% in the second quarter, while wellness visits fell 3.4%. Management assumes an approximately 1.5% decline in U.S. clinical visits during the second half of 2026.
Higher diagnostic intensity, broader testing menus and growth among pets aged five years and older are helping offset weaker traffic. Still, prolonged wellness softness could pressure reference laboratory demand because that testing carries greater exposure to wellness activity.
Based on short-term price targets offered by 13 analysts, the average price target for IDEXX comes to $728.31. The average price target represents an increase of 29.55% from the last closing price.
Image Source: Zacks Investment Research
IDXX Ratings Keep the Earnings Momentum in Check
The raised outlook and margin expansion support the case for durable operating momentum, but softer veterinary traffic, currency volatility and valuation keep the setup balanced. IDXX trades at 34.7X forward 12-month earnings, above the Zacks sub-industry's 26.1X multiple.
The stock currently carries a Zacks Rank #3 (Hold). Its Growth Score of A and Momentum Score of B are favorable, while the Value Score of D points to valuation as a constraint. The VGM Score of B reflects a generally positive blend of growth, momentum and value characteristics, but the #3 Rank supports a measured rather than aggressive stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.